Related Experiment Video
Updated: Jun 13, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
Current issues in the targeted therapy of advanced colorectal cancer
Nikki Knijn1, Jolien Tol, Cornelis J A Punt
1Department of Medical Oncology, Radboud University Nijmegen Medical Centre, Nijmegen, 6500 HB, Netherlands.
Abstract:
Currently used cytotoxic drugs in the treatment of advanced colorectal cancer (ACC) are primarily the fluoropyrimidines, irinotecan, and oxaliplatin. The introduction of targeted therapy has increased the therapeutic arsenal. Two classes of monoclonal antibodies have been approved for clinical use in ACC: bevacizumab, an antibody against the vascular endothelial growth factor (VEGF), and cetuximab and panitumumab, antibodies against the epidermal growth factor receptor (EGFR). We review the current status of targeted therapy and the mechanism of action of monoclonal antibodies in ACC.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Treatment Resistant Cancers
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
